chronic
viral
infect
repres
major
burden
human
health
effect
treatment
remain
unsolv
challeng
one
strike
featur
chronic
diseas
effector
cell
enter
state
dysfunct
also
refer
cell
cell
exhaust
character
gradual
loss
cell
effector
function
consequ
continu
prolong
antigen
exhaust
cell
display
highli
upregul
sustain
express
level
coinhibitori
receptor
fail
prolifer
show
defect
proinflammatori
cytokin
moreov
immunemodulatori
cytokin
like
also
play
import
role
diseas
progress
chronic
infect
shown
polymorph
associ
increas
suscept
chronic
hcv
hbv
importantli
mani
characterist
share
dysfunct
cell
aris
develop
cancer
target
coinhibitori
receptor
emerg
potent
immunemodulatori
strategi
order
revit
antitumor
respons
treatment
condit
tigit
cell
immunoglobulin
itim
domain
coinhibitori
receptor
act
import
immun
checkpoint
limit
celldriven
inflamm
cell
nk
celldepend
antitumor
tigit
express
activ
cell
regulatori
cell
nk
cell
bind
two
ligand
pvr
express
antigenpres
cell
apc
tumor
coactiv
counterpart
compet
tigit
featur
reminisc
pathway
tigit
known
exert
immun
suppress
function
variou
mode
action
includ
direct
indirect
inhibit
cell
shown
cell
intrins
tigit
signal
directli
inhibit
cell
activ
prolifer
attenu
tcr
moreov
demonstr
tigit
express
protect
cell
nkmediat
highlight
role
promot
tumor
progress
regulatori
treg
cell
constitut
express
high
level
tigit
steadi
equip
superior
suppress
capac
indirectli
suppress
effector
cell
addit
tigit
bind
cognat
receptor
dendrit
cell
lead
indirect
suppress
cell
respons
via
induct
immun
suppress
cytokin
importantli
loss
tigit
result
hyperprolif
inflammatori
cell
respons
mark
reduct
key
regul
immun
respons
infect
play
twosid
role
promot
pathogen
well
limit
excess
cell
respons
caus
immun
incident
mani
chronic
latent
human
virus
evolv
encod
homolog
order
evad
immun
nevertheless
resolut
inflammatori
process
reli
tightli
control
balanc
proinflammatori
regulatori
immun
respons
especi
evid
pathogenesi
neurotrop
protozoa
plasmodium
falciparum
trypanosoma
cruzi
toxoplasma
gondii
signal
demonstr
restrict
cytokinemedi
immun
tigit
blockad
defici
shown
lead
breakdown
peripher
toler
hbsagtg
mice
result
develop
hepat
time
tigit
upregul
shown
support
tissu
regener
vivo
neg
regul
nk
cell
thu
better
understand
immunemodulatori
receptor
impact
pathogen
control
well
maintain
tissu
protect
crucial
especi
view
increas
use
checkpoint
inhibitor
clinic
tigit
ligat
function
link
express
known
promot
viru
persist
vivo
also
limit
advers
immunopatholog
damag
tigit
pathway
might
repres
import
regulatori
gatekeep
control
viral
infect
therefor
investig
role
tigit
modul
tcell
respons
follow
chronic
lcmv
infect
well
contribut
restrict
immun
patholog
report
tigit
modul
effect
alter
cytokin
profil
express
level
vivo
howev
tigit
blockad
stimul
alon
suffici
promot
viru
clearanc
persist
rather
play
import
role
limit
immun
patholog
peripher
organ
manner
first
line
investig
sought
identifi
whether
tigit
express
exhaust
cell
upon
chronic
viral
infect
lcmv
clone
classic
model
studi
cell
exhaust
viral
found
tigit
inde
highli
express
cours
chronic
lcmv
clone
infect
cell
well
treg
fig
h
latter
display
highest
express
tigit
throughout
cours
infect
tigit
express
particularli
high
exhaust
cell
fig
cell
next
ask
whether
tigit
also
upregul
antigenspecif
cell
known
becom
exhaust
chronic
viral
infect
order
follow
antigenspecif
cell
tcr
transgen
cell
specif
immunodomin
smarta
peptid
transfer
wildtyp
wt
mice
prior
lcmv
clone
infect
inde
antigenspecif
cell
express
high
level
tigit
chronic
phase
infect
start
day
pi
fig
e
suggest
like
tigit
express
maintain
respons
continu
tcr
stimul
given
cellderiv
shown
contribut
cell
suppress
viral
persist
lcmv
next
test
whether
tigit
express
correl
product
vivo
use
report
mice
carri
bacteri
artifici
chromosom
promotor
transgen
cdna
insert
order
reliabl
identifi
line
tigit
express
exhaust
cell
tigit
cell
display
significantli
higher
level
day
pi
cell
fig
taken
togeth
find
suggest
tigit
mark
exhaust
tcell
popul
aris
chronic
lcmv
infect
order
determin
function
contribut
tigit
pathway
toward
promot
cell
exhaust
chronic
lcmv
infect
target
tigit
vivo
use
block
antitigit
antibodi
clone
gener
character
chronic
infect
mice
continu
treat
either
antitigit
mous
control
antibodi
start
day
infect
observ
tigit
blockad
significantli
alter
exhaust
phenotyp
cell
chronic
phase
infect
day
pi
cell
antitigittr
mice
display
markedli
lower
express
level
control
fig
c
decreas
express
cell
also
detect
earli
phase
lcmv
clone
infect
remain
consider
reduc
day
pi
supplementari
fig
express
also
significantli
decreas
cell
howev
earli
stage
infect
supplementari
fig
express
regulatori
cell
remain
unchang
cours
chronic
infect
vivo
antitigit
antibodi
clone
alreadi
shown
nondeplet
immun
mog
confirm
find
chronic
lcmv
infect
supplementari
fig
lack
tigit
signal
could
also
neg
impact
myeloid
cell
express
ligand
quantifi
abund
variou
popul
antigenpres
cell
spleen
supplementari
fig
e
could
detect
notic
differ
neither
regard
frequenc
absolut
number
moreov
analyz
nk
cell
phenotyp
cours
acut
chronic
lcmv
infect
without
antitigit
ab
administr
found
compar
supplementari
fig
order
determin
whether
tigit
might
abl
activ
promot
tcell
exhaust
infect
wt
mice
intermedi
dose
lcmv
clone
ffu
result
acut
infect
clear
within
day
treat
either
agonist
antitigit
antibodi
isotyp
control
inde
antibodymedi
tigit
engag
result
increas
express
cell
day
pi
fig
result
demonstr
tigit
modul
impact
exhaust
phenotyp
cell
given
shown
contribut
viral
persist
tigit
signal
induc
product
directli
specul
tigit
might
hold
central
role
contribut
viral
persist
abil
induc
investig
link
tigit
express
vivo
chronic
infect
report
lcmv
clone
treat
block
antitigit
antibodi
isotyp
control
tigit
blockad
result
decreas
frequenc
cell
fig
vice
versa
tigit
engag
cours
acut
lcmv
infect
use
agonist
antitigit
antibodi
led
significantli
increas
frequenc
cell
cell
fig
yet
tigit
modul
affect
overal
number
cell
spleen
infect
model
fig
nevertheless
evalu
serum
level
chronic
infect
mice
reveal
earli
drop
around
day
pi
mice
treat
block
antitigit
antibodi
fig
confirm
observ
analyz
supernat
vitro
restimul
splenocyt
chronic
infect
mice
day
pi
line
previou
find
tigit
blockad
correl
significantli
decreas
level
fig
turn
engag
tigit
pathway
acut
infect
mice
result
elev
serum
level
fig
within
cell
compart
effector
cell
display
alter
phenotyp
addit
analyz
express
myeloid
cell
popul
acut
chronic
lcmv
infect
earli
acut
lcmv
infect
could
detect
signific
differ
regard
frequenc
cell
control
agonist
antitigit
antibodytr
mice
supplementari
fig
day
pi
cell
show
significantli
higher
express
treatment
agonist
antitigit
ab
supplementari
fig
mimic
find
observ
cell
compart
howev
overal
frequenc
cell
much
smaller
cell
compart
similarli
observ
differ
express
earli
phase
chronic
lcmv
infect
myeloid
cell
supplementari
fig
found
trend
toward
decreas
express
cell
chronic
stage
infect
supplementari
fig
howev
reach
signific
collect
data
reveal
function
link
tigit
engag
induct
lcmv
infect
cardin
featur
exhaust
cell
hierarch
progress
loss
proinflammatori
cytokin
product
secret
abolish
prior
tnf
secret
cell
exhaust
final
becom
termin
abil
produc
convers
other
previous
shown
agonist
antitigit
antibodi
reduc
proinflammatori
cytokin
product
vitro
thu
next
analyz
whether
tigit
modul
express
proinflammatori
cytokin
cell
acut
chronic
lcmv
infect
agonist
antitigit
antibodi
treatment
acut
lcmv
infect
mice
result
markedli
reduc
product
cell
fig
similarli
cell
also
produc
significantli
lower
amount
restimul
data
shown
furthermor
agonist
antitigit
antibodi
administr
result
pronounc
inhibit
cell
function
day
pi
indic
decreas
express
activ
marker
proinflammatori
cytokin
product
measur
fac
confirm
immun
suppress
properti
supplementari
fig
line
result
tigit
blockad
yield
modest
signific
increas
express
cell
restimul
fig
e
howev
differ
level
product
detect
limit
data
shown
unexpectedli
cell
control
antitigit
antibodi
treat
chronic
infect
mice
display
differ
regard
product
restimul
antigenspecif
manner
fig
taken
togeth
result
demonstr
tigit
blockad
chronic
lcmv
infect
exert
modest
effect
proinflammatori
cytokin
product
cell
wherea
tigit
stimul
acut
infect
effect
inhibit
product
effector
cell
subset
sinc
virusspecif
cell
play
critic
role
viru
clearanc
demonstr
sever
affect
exhaust
delet
follow
high
dose
lcmv
undertook
experi
investig
lcmvspecif
cell
respons
end
adopt
transfer
tcr
transgen
cell
recipi
mice
one
day
prior
chronic
lcmv
clone
infect
strikingli
tigit
blockad
sever
reduc
number
virusspecif
cell
blood
chronic
infect
mice
fig
pattern
observ
endogen
cell
stain
peptidemhci
tetram
fig
concurr
number
cell
significantli
reduc
earli
chronic
infect
fig
even
day
pi
furthermor
contrast
total
cell
transfer
cell
display
elev
coinhibitori
receptor
express
tigit
blockad
fig
well
slightli
reduc
proinflammatori
cytokin
product
day
chronic
lcmv
challeng
fig
f
indic
exhaust
phenotyp
popul
cell
previous
shown
critic
sustain
antivir
immun
respons
chronic
lcmv
infect
subset
serv
sourc
cell
give
rise
differenti
effector
like
cell
respond
checkpoint
blockad
interestingli
found
tigit
blockad
lead
loss
cell
transfer
antigenspecif
endogen
cell
supplementari
fig
b
given
virusspecif
cell
seem
impair
follow
tigit
blockad
total
cell
show
enhanc
product
next
address
inhibit
tigit
pathway
would
affect
viral
load
persist
observ
tigit
blockad
fail
promot
viru
clearanc
spleen
kidney
chronic
infect
anim
fig
h
similarli
found
tigit
stimul
acut
viral
infect
temporarili
impact
viral
titer
viru
gener
clear
day
pi
despit
elev
viru
load
spleen
liver
earli
time
point
day
pi
supplementari
fig
collect
data
suggest
tigit
modul
alon
insuffici
affect
viral
persist
vivo
despit
fact
tigit
modul
affect
viral
load
follow
acut
lcmv
infect
day
pi
notic
mark
differ
regard
bodi
weight
loss
agonist
antitigit
antibodi
treat
mice
fig
control
mice
show
slight
drop
around
initi
bodi
weight
earli
acut
lcmv
infect
observ
agonist
antitigit
antibodi
treat
mice
latter
maintain
even
gain
weight
cours
infect
tigit
engag
allow
effect
modul
turn
play
import
role
resolut
inflamm
variou
infecti
well
autoimmun
hypothes
tigitmedi
induct
could
protect
immun
patholog
lcmv
infect
known
caus
celldepend
liver
thu
sought
test
tigit
stimul
might
limit
tissu
damag
inhibit
cell
activ
infiltr
liver
order
character
quantifi
immun
patholog
chang
measur
serum
level
aspart
aminotransferas
ast
alanin
transaminas
alt
indic
injur
damag
line
hypothesi
found
tigit
engag
result
significantli
decreas
ast
alt
level
day
pi
fig
c
order
better
understand
effect
agonist
antitigit
antibodi
treatment
undertook
histolog
examin
liver
anim
sacrif
day
pi
h
e
stain
liver
reveal
similar
pattern
diseas
experiment
group
could
observ
ongo
parenchym
damag
illustr
presenc
scatter
die
hepatocyt
evid
activ
leukocyt
recruit
infiltr
latter
indic
presenc
leukocyt
lumen
central
vein
roll
along
endotheli
cell
leukocyt
often
appear
activ
leukocyt
infiltr
stretch
central
vein
hepat
cord
fig
leukocyt
infiltr
also
seen
portal
area
random
aggreg
parenchyma
howev
magnitud
histopatholog
chang
overal
diseas
score
significantli
decreas
mice
receiv
agonist
antitigit
antibodi
treatment
especi
regard
portal
vein
inflamm
central
vein
infiltr
fig
collect
find
link
tigit
restrict
immunemedi
liver
damag
acut
lcmv
infect
next
test
whether
involv
mediat
reduc
inflammatori
respons
agonist
antitigit
treat
mice
repeat
acut
lcmv
infect
ko
mice
contrast
wt
mice
agonist
antitigit
treatment
effect
ast
alt
level
ko
mice
fig
c
serum
ast
alt
level
ko
mice
time
point
gener
low
compar
wt
anim
due
acceler
viral
clearanc
henc
faster
resolut
inflamm
ko
mice
supplementari
fig
f
g
howev
analysi
serum
sampl
obtain
day
pi
show
higher
ast
level
ko
comparison
wt
mice
supplementari
fig
e
support
notion
enzym
leakag
liver
occur
consequ
defici
albeit
follow
acceler
kinet
line
result
obtain
day
liver
protect
effect
agonist
antitigit
treatment
depend
ko
mice
show
differ
astalt
level
upon
treatment
day
pi
supplementari
fig
e
import
mediat
tissu
damag
perforin
shown
contribut
celldepend
hepat
model
viral
induc
immun
celldriven
immunopatholog
mice
upon
lcmv
therefor
specul
tigit
might
involv
regul
perforindepend
tissu
damag
follow
acut
viru
infect
order
test
infect
pkob
mice
acut
lcmv
either
treat
control
agonist
antitigit
antibodi
found
effect
tigit
agon
lost
pkob
mice
suggest
patholog
process
inhibit
tigit
perforin
depend
fig
c
determin
whether
tigit
stimul
result
local
product
domin
local
immun
environ
next
analyz
immun
infiltr
liver
acut
lcmv
challeng
inde
agonist
antitigit
antibodi
treat
mice
show
markedli
increas
frequenc
cell
liver
fig
howev
differ
regard
overal
number
cell
data
shown
furthermor
differ
regard
frequenc
cell
liver
could
observ
irrespect
antigenunspecif
specif
restimul
fig
importantli
ratio
cell
strongli
shift
toward
antiinflammatori
cytokin
profil
tissu
antitigittr
group
fig
support
notion
tigit
favor
gener
regul
immun
environ
limit
immunemedi
tissu
damag
manner
test
block
antitigit
antibodi
administr
potenti
exacerb
diseas
sever
tigit
blockad
result
delay
recoveri
chronic
lcmv
infectioninduc
bodi
weight
loss
supplementari
fig
howev
go
along
increas
enzym
leakag
liver
supplementari
fig
along
line
tigit
blockad
neither
lead
increas
tissu
patholog
examin
diseas
model
influenc
viru
load
supplementari
fig
explor
whether
tissueprotect
effect
tigit
restrict
lcmv
infect
whether
repres
gener
featur
tigit
pathway
test
effect
agonist
antitigit
antibodi
influenza
viru
infect
highli
cytopath
viru
antitigit
controltr
wt
ko
mice
infect
mous
adapt
influenza
viru
extent
tissu
damag
lung
determin
day
pi
line
find
lcmv
infect
tigit
pathway
engag
result
significantli
decreas
vascular
leakag
indic
reduc
level
albuminbound
evan
blue
eb
dye
recov
lung
antitigittr
mice
fig
importantli
effect
mediat
challeng
ko
mice
show
revers
phenotyp
agonist
antitigit
antibodi
treatment
compar
isotyp
control
fig
moreov
agonist
antitigit
antibodi
treatment
led
significantli
decreas
frequenc
produc
cell
lung
infect
anim
fig
time
cell
express
markedli
higher
level
compar
control
fig
furthermor
total
number
cell
significantli
increas
lung
tigit
stimul
fig
overal
cytokin
product
lung
antitigit
antibodytr
mice
skew
toward
immun
respons
ratio
cell
greater
anim
fig
addit
protein
level
significantli
elev
lung
homogen
mice
treat
agonist
antitigit
antibodi
compar
control
fig
importantli
antitigit
treatment
effect
influenza
titer
bronchoalveolar
lavag
bal
lung
infect
anim
throughout
cours
infect
supplementari
fig
b
infect
lead
moder
vascul
pronounc
control
mice
also
observ
stronger
evid
ongo
leukocyt
recruit
tissu
evid
higher
frequenc
intens
vascul
control
group
supplementari
fig
taken
togeth
find
support
notion
differ
tissu
damag
infect
result
differenti
viru
replic
tissu
rather
consequ
tigitdepend
immun
modul
summari
data
reveal
import
role
tigit
pathway
limit
immunemedi
tissu
damag
acut
viru
infect
manner
coinhibitori
pathway
serv
central
neg
regul
immun
cell
function
proven
power
target
therapeut
immun
modul
divers
diseas
indic
tigit
inhibitori
pathway
known
play
import
role
limit
autoimmun
well
neg
regul
antitumor
respons
studi
investig
signific
tigit
pathway
modul
cell
function
viral
infect
determin
impact
tigit
blockad
well
tigit
engag
cell
function
phenotyp
chronic
acut
lcmv
infect
respect
found
rather
promot
cell
dysfunct
viral
persist
like
coinhibitori
receptor
tigit
play
critic
role
protect
immun
patholog
vivo
via
induct
immunemodulatori
cytokin
chronic
lcmv
infect
repres
prototyp
model
studi
cell
exhaust
simultan
coexpress
sever
inhibitori
receptor
mark
cell
diminish
effector
found
antibodymedi
tigit
blockad
chronic
lcmv
infect
result
mark
downregul
coinhibitori
receptor
total
cell
cell
contrast
cell
coinhibitori
receptor
express
significantli
lower
throughout
durat
chronic
infect
downregul
transient
cell
occur
earli
stage
infect
might
contribut
dysfunct
sinc
help
describ
essenti
effect
viru
clearanc
tigit
blockad
also
modestli
increas
product
cell
consist
find
tigit
blockad
antibodymedi
tigit
stimul
correl
concomit
induct
cell
support
notion
tigit
least
partial
contribut
develop
cell
exhaust
moreov
found
earli
cell
activ
significantli
reduc
agonist
tigit
ligat
vivo
correl
consider
reduc
product
proinflammatori
cytokin
line
previou
report
demonstr
potenti
tigit
attenu
cell
moreov
abl
establish
tigit
ligat
vivo
result
enhanc
induct
immunosuppress
cytokin
respons
acut
lcmv
challeng
vice
versa
could
verifi
tigit
blockad
lead
diminish
express
cell
chronic
infect
indic
tigit
involv
shift
cytokin
balanc
toward
domin
immun
respons
context
viral
infect
report
differ
group
includ
support
concept
tigit
express
demonstr
correl
express
model
antigenspecif
well
peptid
notabl
tigit
blockad
alon
insuffici
promot
viral
clearanc
lcmv
clone
model
consist
previou
report
show
coblockad
tigit
restor
cytokin
product
exhaust
cell
enhanc
viral
surprisingli
tigit
blockad
result
loss
antigenspecif
cell
could
account
failur
antitigit
treatment
promot
viral
clearanc
one
potenti
mechan
might
contribut
lower
cell
count
could
enhanc
cell
death
consequ
hyperactiv
cell
activationinduc
cell
death
aicd
occur
repeat
stimul
tcr
import
maintain
immun
homeostasi
aicd
also
describ
major
caus
cell
deplet
chronic
infect
independ
direct
cytotox
effect
viru
intriguingli
also
appear
dispens
develop
cell
exhaust
ko
ko
mice
demonstr
harbor
fewer
antigenspecif
cell
control
viru
replic
challeng
chronic
lcmv
clone
contrast
blockad
chronic
viral
infect
restor
function
exhaust
cell
particular
antigenspecif
cell
result
enhanc
cell
respons
viru
control
differ
viru
suggest
two
molecul
oper
distinct
pathway
dampen
immun
cell
respons
might
thu
partak
differ
physiolog
process
immun
suppress
requir
strikingli
lack
signal
shown
associ
pronounc
immun
patholog
increas
mortal
earli
system
lcmv
clone
given
mice
develop
spontan
sign
tempt
specul
tigit
possess
local
role
subordin
lcmv
known
inflict
sever
liver
patholog
consequ
virusspecif
cell
remark
found
antibodymedi
tigit
stimul
significantli
reduc
secret
liverderiv
enzym
ast
alt
blood
confirm
tigit
engag
protect
acut
infect
mice
weight
loss
restrict
leukocyt
infiltr
inflamm
liver
find
could
also
valid
influenza
model
whether
also
translat
improv
surviv
infect
lethal
dose
viru
address
futur
studi
studi
show
engag
tigit
pathway
limit
infectioninduc
liver
lung
damag
manner
thu
reveal
critic
mechanist
aspect
tigit
biolog
fact
amelior
liver
patholog
depend
consist
establish
knowledg
show
particular
essenti
neg
immun
cell
vital
role
protect
immun
patholog
becom
especi
appar
cn
infect
japanes
enceph
viru
infect
coronavirusinduc
enceph
produc
cell
demonstr
improv
surviv
amelior
context
influenza
infect
howev
role
still
remain
controversi
genet
background
appear
domin
effect
diseas
recent
smith
et
al
demonstr
act
directli
cell
increas
antigen
threshold
cell
activ
process
highli
depend
dose
time
sinc
impact
clearli
determin
time
site
product
tigit
modul
might
use
surrog
gener
local
immun
suppress
environ
site
tissu
inflamm
improv
understand
local
effect
checkpoint
inhibitor
could
thu
feed
develop
novel
therapi
treatment
inflammatori
diseas
target
effect
encount
often
interfer
treatment
success
tigit
stimul
might
thu
especi
use
prolong
graft
surviv
manag
side
effect
checkpoint
inhibitor
therapi
combin
checkpoint
inhibitor
conclus
result
extend
previou
knowledg
import
tigit
suppress
immun
cell
activ
show
special
tissueprotect
role
tigit
respons
viral
challeng
mice
purchas
janvier
lab
congen
report
pkob
mice
describ
previous
background
mice
use
week
age
sex
age
match
within
experi
anim
bred
hous
spf
ohb
facil
lasc
switzerland
experi
perform
accord
institut
ethic
polici
nation
regul
review
approv
canton
veterinari
offic
zurich
lcmv
clone
strain
propag
cell
briefli
cell
infect
suspens
use
moi
ml
h
rt
tissu
cultur
flask
tpp
serumfre
modifi
eagl
medium
gibco
plate
shaker
minimum
speed
h
ml
fresh
modifi
eagl
medium
gibco
supplement
fc
corn
lglutamin
gibco
ad
incub
h
supernat
frozen
longterm
storag
work
stock
gener
dilut
frozen
stock
pb
anim
infect
iv
either
ffu
induc
chronic
lcmv
ffu
induc
acut
lcmv
infect
iav
infect
mice
infect
pfu
pfu
follow
antibodi
treatment
day
either
mous
antitigit
antibodi
day
pi
mice
inject
iv
evan
blue
dye
eb
sigma
steril
pb
min
sacrific
anim
perfus
pb
lung
weight
measur
lung
place
ml
formamid
sigma
incub
overnight
amount
extract
evan
blue
eb
dye
measur
photometri
nm
quantifi
standard
curv
use
follow
formula
eb
concentr
ngml
volum
formamid
ml
total
lung
weight
g
influenza
viru
titrat
plaqu
assay
mdck
cell
lcmv
glycoprotein
peptid
peptid
kavynfatm
glngpdiykgvyqfksvefd
purchas
emc
microcollet
gmbh
allophycocyanin
apc
conjug
peptidemhc
class
tetramer
complex
gener
previous
follow
antimous
monoclon
antibodi
use
biolegend
tigit
tnf
mhcii
purchas
cell
signal
technolog
purchas
r
system
granzym
b
purchas
thermo
fisher
dilut
factor
antibodi
use
studi
found
supplementari
tabl
antitigit
mab
blockad
clone
stimul
clone
describ
control
anim
treat
mous
bioxcel
singlecel
suspens
gener
mechan
disrupt
rpmi
medium
gibco
supplement
fc
corn
penicillin
gibco
lglutamin
gibco
red
blood
cell
remov
ad
ack
lysi
buffer
mm
mm
mm
ph
min
splenocyt
stimul
h
presenc
without
addit
antitigit
antibodi
supernat
store
subsequ
cytokin
analysi
cytometr
bead
assay
cba
biolegend
legendplex
kit
bd
cba
kit
use
detect
solubl
protein
accord
manufactur
instruct
raw
data
analyz
legendplex
softwar
biolegend
fcap
array
softwar
soft
flow
inc
calcul
unknown
protein
level
known
standard
curv
mice
inject
ip
either
mous
bioxcel
antitigit
ab
clone
describ
inject
given
day
infect
state
otherwis
chronic
lcmv
infect
treatment
regimen
shorten
accordingli
acut
infect
total
cell
cell
presort
spleen
naiv
smarta
mice
mice
respect
use
mojosort
mous
cell
isol
kit
biolegend
accord
manufactur
instruct
total
cell
per
cell
type
adopt
transfer
iv
recipi
mice
follow
day
recipi
mice
infect
iv
ffu
lcmv
clone
viru
titer
determin
describ
briefli
cell
seed
cellsml
well
plate
modifi
eagl
medium
supplement
fc
psg
organ
sampl
homogen
mechan
disrupt
use
tissuelyserii
qiagen
centrifug
min
full
speed
sampl
serial
dilut
onto
cell
layer
overlay
methylcellulos
dissolv
dmem
medium
gibco
assay
incub
h
day
cell
fix
pfa
min
follow
min
permeabil
triton
cell
layer
wash
twice
pb
follow
h
incub
fc
pb
rt
primari
antibodi
rat
antilcmv
mab
ad
pb
incub
h
rt
cell
wash
twice
pb
incub
secondari
antibodi
peroxidaseconjug
goat
antirat
igg
jackson
immunoresearch
fc
pb
opd
sigmaaldrich
ad
accord
manufactur
instruct
incub
least
min
rt
determin
amount
infecti
iav
particl
canin
kidney
mdck
cell
atcc
seed
plate
dulbecco
modifi
eagl
medium
life
technolog
supplement
fetal
bovin
serum
life
technolog
lglutamin
life
technolog
penicillinstreptomycin
life
technolog
cell
confluenc
cell
wash
pb
supplement
wv
bovin
serum
albumin
bsa
vv
infect
pb
infect
seri
tenfold
dilut
viru
contain
sampl
infect
pb
h
incub
inoculum
remov
cell
cover
agar
overlay
contain
vv
oxoid
agar
sigmaaldrich
dissolv
modifi
eagl
medium
life
technolog
supplement
deae
dextran
sigmaaldrich
vv
sodium
bicarbonat
sigmaaldrich
tpck
treat
trypsin
sigmaaldrich
cell
incub
plaqu
visibl
cell
fix
pfa
min
rt
stain
wv
crystal
violet
sigmaaldrich
methanol
min
fac
stain
perform
singlecel
suspens
spleen
liver
lung
spleen
sampl
prepar
mechan
disrupt
rpmi
medium
supplement
fc
penicillin
lglutamin
liver
lung
enzymat
digest
min
immun
cell
isol
use
percol
ge
healthcar
gradient
red
blood
cell
remov
ad
ack
lysi
buffer
mm
mm
mm
ph
min
cell
restimul
either
peptid
peptid
emc
microcellect
brefeldin
solut
biolegend
h
stain
surfac
stain
antibodi
incub
min
rt
pb
intracellular
cytokin
stain
spenocyt
permeabil
use
cytofixcytoperm
kit
bd
bioscienc
min
rt
follow
antibodi
incub
min
rt
stain
transcript
factor
cell
stain
permeabil
factor
stain
buffer
set
ebiosci
zombi
nir
fixabl
dye
use
exclud
dead
cell
debri
data
acquir
bd
lsr
fortessa
bd
fac
cantoii
analyz
bd
bioscienc
analyz
use
flowjo
softwar
treestar
gate
strategi
shown
supplementari
fig
liver
lung
lobe
antitigit
ab
treat
uninfect
mice
fix
paraformaldehyd
transfer
etoh
storag
process
organ
trim
routin
paraffin
wax
embed
consecut
section
prepar
routin
stain
hematoxylineosin
subject
period
acid
schiff
pa
reaction
demonstr
hepatocellular
glycogen
accumul
liver
assess
histopatholog
chang
includ
leukocyt
infiltr
singl
blind
experiment
setup
pathologist
unawar
clinic
statu
treatment
mice
receiv
histopatholog
chang
grade
basi
assess
scheme
publish
ishak
et
thoolen
et
follow
histolog
featur
consid
leukocyt
infiltr
portal
area
around
central
vein
random
focal
aggreg
hepatocyt
death
necrosi
apoptosi
distribut
chang
character
focal
multifoc
diffus
grade
serum
ast
alt
measur
clinic
chemistri
depart
univers
hospit
zurich
switzerland
catalyt
concentr
enzym
measur
pyridox
phosphat
activ
roch
coba
accord
ifcc
statist
analys
perform
use
graphpad
prism
appropri
statist
test
select
indic
figur
legend
signific
differ
mark
figur
differ
control
treatment
group
determin
use
twotail
student
test
includ
welch
correct
unequ
variant
necessari
compar
two
group
use
oneway
anova
tukey
multipl
comparison
test
histopatholog
data
evalu
use
twotail
test
signific
defin
p
p
p
ns
signific
p
inform
research
design
avail
natur
research
report
summari
link
articl
